Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) is a key oncogenic target in cancer, mediating critical cellular processes.
• Current EGFR inhibitors, including TKIs and mAbs, face limitations due to drug resistance and cancer heterogeneity.
• Alterations in EGFR's catalytic structural domain pose significant challenges for conventional targeted therapies.

Purpose of the Study:

• To provide a comprehensive overview of the development of PROTACs targeting EGFR for cancer therapy.
• To highlight the advantages of PROTACs over traditional EGFR inhibitors.
• To discuss the challenges and future opportunities in the field of EGFR-targeted PROTACs.

Main Methods:

• Review of recent advancements in the design and application of heterobifunctional EGFR PROTACs.
• Analysis of PROTACs utilizing wild-type (WT) and mutated EGFR TKIs.
• Comparison of PROTACs with conventional EGFR inhibitors based on cellular inhibition, potency, and toxicity.

Main Results:

• PROTACs leverage intracellular protein destruction pathways, bypassing limitations of occupancy-driven small molecules.
• EGFR PROTACs have demonstrated superior cellular inhibition and potency compared to traditional EGFR TKIs.
• PROTACs exhibit improved toxicity profiles and enhanced effectiveness against drug-resistant cancer models.

Conclusions:

• PROTACs represent a promising emerging therapy for targeting EGFR in cancer.
• The development of EGFR-targeted PROTACs offers a strategy to overcome existing therapeutic limitations.
• Further research into EGFR PROTACs holds significant potential for advancing cancer treatment.